Studies on Fluorinated Annulated Nicotines: Concise Synthesis of cis-4,4-Difluoro-2,3,3a,4,5,9b-hexahydro-1-methyl-1H-pyrrolo[2,3-f]quinoline

Abstract

A fused 6,6,5-tricyclic difluorinated nicotine analogue was efficiently assembled in five steps in 36% overall yield. The conformation-restricting unit is a six-membered fluorinated carbocycle. The gem-difluoromethylene group was introduced through an indium-promoted Barbier allylation of 3-bromo-3,3-difluoropropene. The construction of the tricyclic skeleton was achieved using an intramolecular azomethine ylide-alkene [3+2] cycloaddition.

fluorinated - intramolecular azomethine ylide-alkene-[3+2] cycloaddition - nicotine analogue - rigid conformation

References and Notes

1a Wagner FF. Comins DL. Tetrahedron  2007,  63:  8065 

1b Hukkanen J. Jacob P. Benowitz NL. Pharmacol. Rev.  2005,  57:  79 

1c Breining SR. Curr. Top. Med. Chem.  2004,  4:  609 

1d Decker MW. Aneric SP. Neuronal Nicotinic Recept.  1999,  395 

1e Villemagne VL. Musachio JL. Scheffel U. Neuronal Nicotinic Recept.  1999,  235 

1f Glennon RA. Dukat M. Med. Chem. Res.  1996,  465 

1g McDonald IA. Cosford N. Vernier J.-M. Annu. Rep. Med. Chem.  1995,  30:  41 

1h Glennon RA. Maarouf A. Fahmy S. Martin B. Fan F. Yousif M. Shafik RM. Dukat M. Med. Chem. Res.  1993,  2:  546 

For our previous work, see:

2a Sang Y. Zhao J. Jia X. Zhai H. J. Org. Chem.  2008,  73:  3589 

2b Yang X. Luo S. Fang F. Liu P. Lu Y. He M. Zhai H. Tetrahedron  2006,  62:  2240 

2c Luo S. Fang F. Zhao M. Zhai H. Tetrahedron  2004,  60:  5353 

2d For a part of Rapoport’s work, see: Zhai H. Liu P. Luo S. Fang F. Zhao M. Org. Lett.  2002,  4:  4385 

2e Lennox JR. Turner SC. Rapoport H. J. Org. Chem.  2001,  66:  7078 

2f Turner SC. Zhai H. Rapoport H. J. Org. Chem.  2000,  65:  861 

2g For representative work from other labs, see: Xu Y.-z. Choi J. Calaza MI. Turner SC. Rapoport H. J. Org. Chem.  1999,  64:  4069 

2h Ondachi PW. Comins DL. Tetrahedron Lett.  2008,  49:  569 

2i Comins DL. Laura S. King LS. Smith ED. Février FC. Org. Lett.  2005,  7:  5059 

2j Meijler MM. Matsushita M. Altobell LJ. Wirsching P. Janda KD. J. Am. Chem. Soc.  2003,  125:  7164 

2k Sarkar TK. Basak S. Slanina Z. Chow TJ.
J. Org. Chem.  2003,  68:  4206 

2l Ullrich T. Binder D. Pyerin M. Tetrahedron Lett.  2002,  43:  177 

2m Kanne DB. Abood LG. J. Med. Chem.  1988,  31:  506 

2n Glassco W. Suchocki J. George C. Martin BR. May EL. J. Med. Chem.  1993,  36:  3381 

2o Chavdarian CG. Seeman JI. Wooten JB. J. Org. Chem.  1983,  48:  492 

2p Wei ZL. Xiao YX. Yuan HB. Baydyuk M. Petukhov PA. Musachio JL. Kellar KJ. Kozikowski AP. J. Med. Chem.  2005,  48:  1721 

2q Chellappan SK. Xiao Y. Kellar KJ. Kozikowski AP. 231st ACS National Meeting, Atlanta, GA, 2006   American Chemical Society; Washington DC: 2006, Abstract MEDI-159

3 Spande TF. Garraffo HM. Edwards MW. Yeh HJC. Pannell L. Daly JW. J. Am. Chem. Soc.  1992,  114:  3475 

4a Rivkin A. Biswas K. Chou T.-C. Danishefsky SJ. Org. Lett.  2002,  4:  4081 

4b Sugimoto Y. Konoki K. Murata M. Matsushita M. Kanazawa H. Oishi T. J. Med. Chem.  2009,  52:  798 

4c Shah P. Westwell AD. J. Enzym. Inhib. Med. Chem.  2007,  22:  527 

For recent reviews, see:

5a Thayer AM. Chem. Eng. News  2006,  (June 5):  15 

5b Begue JP. Bonnet-Delpon D. J. Fluorine Chem.  2006,  127:  992 

5c Kirk KL. J. Fluorine Chem.  2006,  127:  1013 

5d For recent excellent overviews, see: Ojima I. ChemBioChem  2004,  5:  628 

5e Chambers RD. Fluorine in Organic Chemistry   Blackwell; Oxford: 2004. 

5f Kirsch P. Modern Fluoroorganic Chemistry   Wiley-VCH; Weinheim: 2004. 

5g Uneyama K. Organofluorine Chemistry   Blackwell; Oxford: 2006. 

6a You Z.-W. Jiang Z.-X. Wang B.-L. Qing F.-L. J. Org. Chem.  2006,  71:  7261 

6b Zhang X. Xia H. Dong X. Jin J. Meng W.-D. Qing F.-L. J. Org. Chem.  2003,  68:  9026 

7

The reagent, 3-bromo-3,3-difluoropropene, is available from the TCI Company, although we obtained it as a gift from Professors G. Zhao and F.-L. Qing of the Shanghai Institute of Organic Chemistry (see also Acknowledgment).

8a Chavdarian CG. Seeman JI. Wooten JB. J. Org. Chem.  1983,  48:  492 

8b Xu R. Dwoskin LP. Grinevich V. Sumithran SP. Crooks PA. Drug Dev. Res.  2002,  55:  173 

8c Crooks PA. Ayers JT. Xu R. Sumithran SP. Grinevich VP. Wilkins LH. Deaciuc AG. Allen DD. Dwoskin LP. Bioorg. Med. Chem. Lett.  2004,  14:  1869 

9a Xu R. Dwoskin LP. Grinevich VP. Deaciuc G. Crooks PA. Bioorg. Med. Chem. Lett.  2001,  11:  1245 

9b Crooks PA. Dwoskin LP. Grinevich VP. Xu R. PCT Int. Appl. WO 2002057275, 2002 , 

9c Papke RL. Zheng G. Horenstein NA. Dwoskin LP. Crooks PAC. Bioorg. Med. Chem. Lett.  2005,  15:  3874 

10 Chezal JM. Moreau E. Desbois N. Blache Y. Chavignon O. Teuladea JC. Tetrahedron Lett.  2004,  45:  553 

11a Kirihara M. Takuwa T. Takizawa S. Momose T. Tetrahedron Lett.  1997,  38:  2853 

11b Percy JM. Pintat S. Chem. Commun.  2000,  607 

11c Audouard C. Fawcett J. Griffiths GA. Percy JM. Pintat S. Smith CA. Org. Biomol. Chem.  2004,  2:  528 

11d Kargbo RB. Cook GR. Curr. Org. Chem.  2007,  11:  1287 

12

The acetal deprotection proceeded much faster when the acid used was switched from oxalic acid to TsOH×H₂O.

For intramolecular azomethine ylide-alkene [3+2] cycloaddition, see:

13a Smith R. Livinghouse T. Tetrahedron  1985,  41:  3559 

13b Bolognesi ML. Andrisano V. Bartolini M. Minarini A. Rosini M. Tumiatti V. Melchiorre C. J. Med. Chem.  2001,  44:  105 

14 Sato K. Nishimoto T. Tamoto K. Omote M. Ando A. Kumadaki I. Heterocycles  2002,  56:  403 

15

Preparation of New Compounds
Compound 5 Indium powder (67 mg, 0.58 mmol) and 3-bromo-3,3-difluoropropene (70 µL, 0.72 mmol) were added sequen-tially to a solution of 4 (94 mg, 0.45 mmol) in DMF (3 mL). The mixture was then sonicated for 3 h. After evaporation of DMF under reduced pressure, sat. aq NaHCO₃ soln and EtOAc were added. The two layers were separated, and
the aqueous layer was further extracted with EtOAc. The combined organic layers were dried (Na₂SO₄), filtered, and concentrated to give a residue, which was chromatographed (EtOAc-PE, 1:5) to afford 5 (100 mg, 78%) as a colorless oil: ^¹H NMR (300 MHz, CDCl₃): δ = 1.16 (t, J = 9.2 Hz, 3 H), 1.27 (t, J = 9.9 Hz, 3 H), 3.36-3.50 (m, 2 H), 3.54-3.65 (m, 1 H), 3.74-3.82 (m, 1 H), 4.99 (d, J = 9.6 Hz, 1 H), 5.36-5.45 (m, 1 H), 5.49 (d, J = 11.1 Hz, 1 H), 5.61-5.69 (m, 1 H), 5.88 (s, 1 H), 5.92-6.02 (m, 1 H), 7.31 (dd, J = 7.8, 4.5 Hz, 1 H), 8.04 (dd, J = 7.8, 1.5 Hz, 1 H), 8.53 (dd, J = 4.7, 1.7 Hz, 1 H). ^¹³C NMR (75 MHz, CDCl₃): δ = 15.0, 15.0, 60.2, 63.2, 70.4 (t, J = 31.1 Hz), 97.7 (t, J = 4.6 Hz), 120.1 (t, J = 244.8 Hz), 121.1 (t, J = 9.6 Hz), 123.4, 129.8 (t, J = 25.4 Hz), 133.7, 135.6, 147.7, 152.3 (d, J = 5.4 Hz). ^¹9F NMR (282 MHz, CDCl₃): δ = -109.59 (dm, J = 249.2 Hz, 1 F), -104.12 (dm, J = 248.7 Hz, 1 F). MS (MALDI): m/z = 310.1 [M + Na], 289.1 [M + 2H], 288.1
[M + H]. HRMS (MALDI): m/z calcd for C₁₄H₁₉NO₃F₂ + H: 288.1411; found: 288.1414.
Compounds 6a,b To a soln of 5 (108 mg, 0.38 mmol) in acetone and H₂O (1:1, 8 mL) was added PTSA˙H₂O (143 mg, 0.75 mmol). The mixture was heated at reflux for 2 h, cooled to r.t., neutralized with sat. aq NaHCO₃ soln, and extracted with EtOAc. The combined organic layers were dried (MgSO₄), filtered, and concentrated. The residue was chromatog-raphed (EtOAc-PE, 1:1) to give a mixture of 6a and 6b (9:1, 71 mg, 89%) as a colorless oil. ^¹H NMR [300 MHz, CDCl₃, three compounds (two hemiacetals and one aldehyde), 0.49:0.42:0.09]: δ = 3.68 (d, J = 9.6 Hz, 0.42 H, 0.42 OH), 4.46 (d, J = 7.2 Hz, 0.49 H, 0.49 OH), 5.18-5.26 (m, 0.42 H), 5.26-5.29 (m, 0.09 H), 5.38-5.44 (m, 0.49 H), 5.48-2.62 (m, 1 H), 5.82-5.70 (m, 1 H), 5.93-6.07 (m, 0.49 H), 6.12-6.25 (m, 0.42 H), 6.49 (d, J = 9.9 Hz, 0.42 H), 6.65 (d, J = 5.7 Hz, 0.49 H), 7.35-7.39 (m, 0.91 H), 7.56 (dd, J = 7.7, 5.0 Hz, 0.09 H), 7.80-7.84 (m, 0.91 H), 8.28 (d, J = 8.1 Hz, 0.09 H), 8.66-8.69 (m, 0.91 H), 8.80 (d, J = 4.2 Hz, 0.09 H), 10.30 (s, 0.1 H) [0.1 H missing (0.1 OH)]. ^¹9F NMR (282 MHz, CDCl₃): δ = -111.29 (dt, J = 251.4, 11.8 Hz, 0.09 F), -110.33 (dt, J = 251.5, 10.9 Hz, 0.49 F),
-110.13 (dt, J = 251.3, 11.8 Hz, 0.42 F), -108.22 (dt, J = 251.5, 12.4 Hz, 0.42 F), -107.89 (dt, J = 251.3, 9.6 Hz, 0.49 F), -105.58 (dm, J = 251.4 Hz, 0.09 F). MS (EI): m/z (%) = 213 [M⁺], 136 (100). Anal. Calcd for C₁₀H₉F₂NO₂: C, 56.34; H, 4.26; N, 6.57. Found: C, 56.44; H, 4.48; N, 6.70. Compounds 7 A soln of 6 (222 mg, 1.04 mmol) and sarcosine (98%, 139 mg, 1.56 mmol) in toluene (18 mL) was heated at reflux under N₂ overnight, cooled to r.t., and concentrated. The residue was diluted with brine and extracted with EtOAc. The combined organic layers were dried (MgSO₄), filtered, and concentrated. The residue was chromatographed (EtOAc-PE, 1:1) to give a pair of diastereomers of 7 (dr = 9:1, 171 mg, 68%) as a white solid: mp 82-83 ˚C (dec.). ^¹H NMR (300 MHz, CDCl₃): δ = 2.18 (s, 3 H), 2.11-2.30 (m, 1 H), 2.33-2.42 (m, 1 H), 2.45-2.53 (m, 1 H), 2.93-3.07 (m, 1 H), 3.23-3.29 (m, 2 H), 4.75 (d, J = 7.8 Hz, 0.9 H), 5.17 (d, J = 23.4 Hz, 0.1 H), 6.30 (s, 1 H), 7.30-7.34 (dd, J = 7.8, 5.1 Hz, 1 H), 7.54 (d, J = 8.1 Hz, 0.1 H), 7.60 (d, J = 7.5, 1.2 Hz, 0.9 H), 8.56 (d, J = 4.8 Hz, 0.1 H), 8.61 (dd, J = 5.1, 1.2 Hz, 0.9 H). ^¹9F NMR (282 MHz, CDCl₃): δ =
-115.82 (d, J = 238.8 Hz, 0.1 F), -111.39 (dm, J = 249.7 Hz, 0.9 F), -109.14 (dm, J = 238.8 Hz, 0.1 F), -88.52 (dm, J = 249.7 Hz, 0.9 F). ESI-MS: m/z = 483.0 [2M + H], 263.0 [M + Na], 240.9 [M + H]. Anal. Calcd for C₁₂H₁₄F₂N₂O: C, 59.99; H, 5.87; N, 11.66. Found: C, 59.84.; H, 6.06; N, 11.25. Compound 2b To a suspension of NaH (60% in mineral oil, 34 mg, 0.86 mmol) in dry THF (10 mL) under N₂ was added a soln of 7 (103 mg, 0.43 mmol) in dry THF (2 mL). After the mixture was stirred at r.t. for 30 min, CS₂ (80 µL, 1.29 mmol) was added and stirring continued for 1 h. Iodomethane (30 µL, 0.47 mmol) was then added. After stirring for another 0.5 h, the reaction was quenched with sat. aq NaHCO₃ soln and the mixture was extracted with EtOAc. The combined organic layers were dried (Na₂SO₄), filtered, and concentrated. The residue was chromatographed (EtOAc-PE, 1:10) to afford the xanthates (138 mg, 97%) as a colorless oil. To a solution of above-mentioned xanthates (138 mg, 0.42 mmol) in anhyd toluene (36 mL) were added n-Bu₃SnH (97%, 0.14 mL, 0.50 mmol) and AIBN (14 mg, 0.08 mmol). The mixture was stirred at reflux overnight, cooled to r.t., concentrated, diluted with sat. aq NaHCO₃ soln, and extracted with EtOAc. The combined organic extracts were dried (Na₂SO₄), filtered, and concentrated. The residue was chromatographed (EtOAc-PE, 1:1) to afford 2b (74 mg, 79%) as a colorless oil. ^¹H NMR (300 MHz, CDCl₃): δ = 1.79-2.23 (m, 2 H), 2.29-2.41 (m, 1 H), 2.32 (s, 3 H), 2.96-3.13 (m, 2 H), 3.23-3.34 (m, 2 H), 3.60 (dd, J = 33.9, 15.0 Hz, 1 H), 7.21 (dd, J = 7.2, 4.8 Hz, 1 H), 7.49 (d, J = 7.2 Hz, 1 H), 8.49 (d, J = 4.8 Hz, 1 H). ^¹³C NMR (100 MHz, CDCl₃): δ = 25.3 (t, J = 6.0 Hz), 38.4 (t, J = 26.4 Hz), 40.0, 45.0 (dd, J = 26.1, 26.1 Hz), 56.0, 67.3 (d, J = 7.4 Hz), 121.8, 125.9 (dd, J = 244.9, 205.7 Hz), 130.2, 136.4, 148.6, 153.7 (d, J = 11.2 Hz). ^¹9F NMR (282 MHz, CDCl₃): δ = -101.41 (d, J = 242.4 Hz, 1 F), -90.0 (dm, J = 242.4 Hz, 1 F). ESI-MS: 225.2 [M + H]. HRMS (EI): m/z calcd for C₁₂H₁₄N₂F₂: 224.1125; found: 224.1118.